ID

22316

Description

XELODA and Lapatinib Advanced or Metastatic Breast Cancer Study ID: 100151 Clinical Study ID: EGF100151 Study Title: A Phase III, Randomized, Open-label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) versus Capecitabine in Women with Refractory Advanced or Metastatic Breast Cancer Clinicaltrials.gov Identifier: NCT00078572 https://clinicaltrials.gov/ct2/show/NCT00078572 Procedure: Blood products Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: lapatinib Trade Name: Tyverb,Tykerb,Tycerb Study Indication: Breast Cancer; Neoplasms, Breast

Link

https://clinicaltrials.gov/ct2/show/NCT00078572

Keywords

Versions (1)
  1. 5/29/17 5/29/17 -
Uploaded on

May 29, 2017

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

XELODA and Lapatinib Advanced or Metastatic Breast Cancer Blood products NCT00078572

English

XELODA and Lapatinib Advanced or Metastatic Breast Cancer Blood products NCT00078572

1 forms  
Blood products
Description

Blood products

Alias
UMLS CUI-1
C0456388
Were any blood products given to the subject at any time between 2 weeks prior to the first dose of investigational product and 30 days post discontinuation of investigational product?
Description

blood products

Data type

text

Alias
UMLS CUI [1]
C0456388
Date started
Description

If YES, record below:

Data type

date

Alias
UMLS CUI [1,1]
C0808070
UMLS CUI [1,2]
C0456388
Blood product
Description

Blood product

Data type

integer

Alias
UMLS CUI [1,1]
C0456388
UMLS CUI [1,2]
C0332307
Blood product, if other please specify
Description

Blood product

Data type

text

Alias
UMLS CUI [1,1]
C0456388
UMLS CUI [1,2]
C0332307
Back to the top of the page

Similar models

XELODA and Lapatinib Advanced or Metastatic Breast Cancer Blood products NCT00078572

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Blood products
C0456388 (UMLS CUI-1)
Item
Were any blood products given to the subject at any time between 2 weeks prior to the first dose of investigational product and 30 days post discontinuation of investigational product?
text
C0456388 (UMLS CUI [1])
blood products
Code List
Were any blood products given to the subject at any time between 2 weeks prior to the first dose of investigational product and 30 days post discontinuation of investigational product?
CL Item
Yes (Y)
CL Item
No (N)
Date started
Item
Date started
date
C0808070 (UMLS CUI [1,1])
C0456388 (UMLS CUI [1,2])
Item
Blood product
integer
C0456388 (UMLS CUI [1,1])
C0332307 (UMLS CUI [1,2])
Blood product
Code List
Blood product
CL Item
Whole blood (1)
CL Item
Red cells (2)
CL Item
Platelets - concentrate  (3)
CL Item
Plasma - FFP (4)
CL Item
Cryoprecipitate (5)
CL Item
Factor VIII (6)
CL Item
Other, specify text in the box (99)
Blood product
Item
Blood product, if other please specify
text
C0456388 (UMLS CUI [1,1])
C0332307 (UMLS CUI [1,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial